Nasdaq-listed ImmunoGen has hired Daniel Char as senior vice president and chief legal officer.
Char previously worked at Evelo Biosciences as general counsel and corporate secretary, providing counsel and operational support on business and legal issues such as business development, commercialization, healthcare fraud and intellectual property.
Before joining Evelo, he was associate general counsel and assistant secretary at Smith+Nephew, having previously been general counsel and secretary at Targanta Therapeutics, senior associate general counsel at Idenix Pharmaceuticals and associate general counsel at Biogen.
Char succeeds Joseph Kenny, who has been acting general counsel and vice president since March 2020 and who will remain with the company as associate general counsel.
ImmunoGen operates in the field of antibody-drug conjugates for the treatment of cancer.
Mark Enyedy, the company’s president and CEO, says in a statement: ‘We are pleased to welcome Daniel to ImmunoGen to lead our legal team and join [our] executive committee. With his deep expertise advising on commercial, regulatory, compliance and corporate governance matters, Daniel will play an important role as we increase the scale and complexity of the business.’